Atlizumab or tocilizumab

SNG-CD123A (anti-IL-3Ra) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML).

SNG-CD123A (anti-IL-3Ra) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML).

Sonepcizumab (anti-Sphingosine-1-phosphate) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab (anti-Sphingosine-1-phosphate) has the potential for the research of metastatic renal cell carcinoma (mRCC).Purity&gt:95%

Sonepcizumab (anti-Sphingosine-1-phosphate) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab (anti-Sphingosine-1-phosphate) has the potential for the research of metastatic renal cell carcinoma (mRCC).Purity&gt:95%

Sonepcizumab (anti-Sphingosine-1-phosphate) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab (anti-Sphingosine-1-phosphate) has the potential for the research of metastatic renal cell carcinoma (mRCC).Purity&gt:95%

Talacotuzumab (anti-IL-3Ra) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab (anti-IL-3Ra) has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V,

Talacotuzumab (anti-IL-3Ra) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab (anti-IL-3Ra) has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V,

Talacotuzumab (anti-IL-3Ra) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab (anti-IL-3Ra) has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V,

Talacotuzumab (anti-IL-3Ra) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab (anti-IL-3Ra) has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V,

Tildrakizumab (anti-IL-23a) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab (anti-IL-23a) has high-affinity for single-chain IL-23 (Kd: 136 pM).

Tildrakizumab (anti-IL-23a) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab (anti-IL-23a) has high-affinity for single-chain IL-23 (Kd: 136 pM).

Tildrakizumab (anti-IL-23a) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab (anti-IL-23a) has high-affinity for single-chain IL-23 (Kd: 136 pM).